On August 8, 2023, Atara Biotherapeutics will unveil its financial results for the second quarter of 2023. Market analysts anticipate an earnings per share (EPS) of $-0.67. Investors who support Atara Biotherapeutics will be eagerly awaiting the announcement, hoping for not only surpassing this estimate but also receiving positive guidance or a forecast of growth for the upcoming quarter. It is worth noting that the impact on stock prices is often determined by guidance rather than meeting or missing earnings expectations. In the previous quarter, the company fell short of the EPS by $0.33, resulting in a 17.85% decline in share value the following day. As of August 4, Atara Biotherapeutics’ shares were trading at $2.3, with a 51.92% decrease over the past 52 weeks. Stay updated on all of Atara Biotherapeutics’ earnings releases by visiting their website’s earnings calendar.
ATRA Stock Performance and Financial Analysis: August 7, 2023
On August 7, 2023, ATRA stock had a relatively stable performance, with a slight increase in value. The stock opened at $2.32, slightly higher than the previous day’s close of $2.31. Throughout the day, it traded within a range of $2.24 to $2.40. The trading volume for the day was 61,767 shares, which is significantly lower than the average volume of 1,732,712 shares over the past three months.
ATRA, with a market capitalization of $224.4 million, operates in the Health Technology sector and is categorized under the Pharmaceuticals: Major industry. The company has shown strong revenue growth in the past year, with a growth rate of 212.55%. However, its earnings growth has been less impressive, with a decline of 11.75% expected for the current year. In the previous year, ATRA experienced a positive earnings growth of 38.36%.
The stock’s price-to-sales ratio is 5.26, indicating that investors are willing to pay 5.26 times the company’s annual revenue for each share of stock. The price-to-book ratio is 1.73, suggesting that the stock is trading at a reasonable valuation compared to its book value.
ATRA does not have a P/E ratio listed, which could be due to negative earnings or lack of earnings data. The company’s net profit margin is -359.12%, indicating that it has been operating at a loss.
In terms of performance compared to other stocks, ATRA had a neutral day. Molecular Partners A and CorMedix Inc experienced no change and a decrease of 3.41% in their stock prices, respectively. On the other hand, BioXcel Therapeutics saw an increase of 1.07% in its stock price, while X4 Pharmaceuticals Inc experienced a decrease of 6.21%.
Looking ahead, ATRA’s next reporting date is scheduled for August 9, 2023. Analysts forecast an earnings per share (EPS) of -$0.66 for the current quarter. In the previous year, the company reported an annual revenue of $63.6 million but incurred a net loss of -$228.3 million.
ATRA is headquartered in Thousand Oaks, California, but there are no executives listed for the company.
In conclusion, ATRA stock had a relatively stable performance on August 7, 2023, with a slight increase in value. The company has shown strong revenue growth but has struggled with earnings. Investors should closely monitor the upcoming earnings report on August 9, 2023, to gain further insights into the company’s financial performance.
Atara Biotherapeutics Inc (ATRA) Stock Performance and Analyst Outlook: August 7, 2023
On August 7, 2023, Atara Biotherapeutics Inc (ATRA) displayed an interesting performance in the stock market. The 7 analysts offering 12-month price forecasts for ATRA had a median target of $20.00, with a high estimate of $31.00 and a low estimate of $2.00. This median estimate indicated a significant increase of 788.89% from the last price of $2.25.
The consensus among 9 polled investment analysts was to buy stock in Atara Biotherapeutics Inc. This rating has remained steady since June, indicating a consistent positive sentiment towards the company’s stock.
The current quarter’s earnings per share for ATRA were reported as -$0.66, which suggests a loss for the company.
In terms of sales, Atara Biotherapeutics Inc reported $4.4 million for the current quarter.
Investors should also keep an eye on the reporting date of August 9, which suggests that Atara Biotherapeutics Inc will release its financial results for the current quarter on that day.
Overall, the stock performance of Atara Biotherapeutics Inc on August 7, 2023, was influenced by the positive outlook from analysts, indicating a significant potential increase in the stock price. However, investors should conduct thorough research and consider various factors, including the company’s financial results, market position, and long-term prospects, before making any investment decisions.